Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Julieann Sludden.

Newcastle AuthorsTitleYearFull text
Dr Shelby Barnett
Julie Errington
Julieann Sludden
Dr David Jamieson
Professor Gareth Veal
et al.
Pharmacokinetics and pharmacogenetics of cyclophosphamide in a neonate and infant childhood cancer patient population2021
Monique Zangarini
Philip Berry
Julieann Sludden
Professor Gareth Veal
Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma2017
Dr David Jamieson
Dr Nicola Sunter
Sara Muro
Dr Nicola Cresti
Julieann Sludden
et al.
Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide2017
Dr David Jamieson
Melanie Griffin
Julieann Sludden
Dr Yvette Drew
Dr Nicola Cresti
et al.
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours2016
Professor Gareth Veal
Julieann Sludden
Dr David Jamieson
Julie Errington
Dr Ghada Malik
et al.
Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin’s lymphoma2016
Dr Yvette Drew
Dr Martin Highley
Julieann Sludden
Dr James Murray
Dr David Jamieson
et al.
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly (ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer2016
Dr James Murray
Julieann Sludden
Professor Alan Boddy
Professor Nicola Curtin
Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System2015
Dr David Jamieson
Dr Jo Lee
Dr Nicola Cresti
Melanie Griffin
Julieann Sludden
et al.
Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil2014
Professor Ruth Plummer
Professor Alan Boddy
Julieann Sludden
A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours2011
Dr David Jamieson
Dr Nicola Cresti
Julieann Sludden
Melanie Griffin
Nahed Hawsawi
et al.
Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy2011
Julieann Sludden
Melanie Griffin
Mike Cole
Dr Mark Verrill
Dr David Jamieson
et al.
Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide2010
Professor Ruth Plummer
Melanie Griffin
Dr Sally Coulthard
Julieann Sludden
Professor Alan Calvert
et al.
Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors2009
Dr Jo Lee
Dr Mark Verrill
Julieann Sludden
Melanie Griffin
Sharon Erb
et al.
Pharmacogenetic influences on outcome from AC chemotherapy in the treatment of breast cancer2007
Professor Alan Boddy
Julieann Sludden
Melanie Griffin
Professor Herbie Newell
Professor Stephen O'Brien
et al.
Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia2007
Dr Jo Lee
Julieann Sludden
Professor Alan Boddy
Dr Mark Verrill
Investigation of multi-drug resistance 1 (MDR1) and cytochrome P4502C8 (CYP2C8) pharmacogenetics on outcome from treatment of advanced breast cancer using paclitaxel in a UK national trial of a weekly versus 3-weekly schedule.2006
Mark Leslie
Julieann Sludden
Professor Ruth Plummer
Dr Alastair Greystoke
Professor Alan Calvert
et al.
A phase I and pharmacodynamic study of a 7 day infusion schedule of the DNMT1 antisense compound MG98.2005
Professor Alan Boddy
Professor Ruth Plummer
Julieann Sludden
Melanie Griffin
Dr Mark Verrill
et al.
A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules2005
Professor Gareth Veal
Julie Errington
Julieann Sludden
Melanie Griffin
Annie Parry
et al.
Determination of anti-cancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry2003
Julie Errington
Professor Gareth Veal
Julieann Sludden
Melanie Griffin
Professor Andrew Pearson
et al.
Determination of the anti-cancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry2003
Dr Mark Verrill
Professor Alan Boddy
Julieann Sludden
Kevin Fishwick
Lynsey Robson
et al.
Phase 1 pharmacokinetic (PK) study of CT-2103 given Q2 or Q3 weeks in patients with solid tumors2003
Professor Alan Boddy
Dr Mark Verrill
Julieann Sludden
Kevin Fishwick
Lynsey Robson
et al.
Pharmacological study of CT-2103 (XyotaxTM), a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks or every 2 weeks in a phase I study2002
Dr Andrew Simpson
Dr Paula Calvert
Julieann Sludden
Professor Alan Boddy
Melanie Griffin
et al.
Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules2002
Professor Alan Boddy
Melanie Griffin
Julieann Sludden
Huw Thomas
Kevin Fishwick
et al.
Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer2001
Professor Alan Boddy
Dr Mark Verrill
Julieann Sludden
Melanie Griffin
Kevin Fishwick
et al.
Phase I and pharmacological study of CT-2103, a poly(L-glutamic acid)-paclitaxel conjugate2001
Julieann Sludden
Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations2000
Professor Alan Boddy
Melanie Griffin
Julieann Sludden
Huw Thomas
Kevin Fishwick
et al.
Paclitaxel and carboplatin dose-intensity and duration of infusion in the treatment of ovarian cancer2000
Dr Gordon Strathdee
Julieann Sludden
Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter2000
Julieann Sludden
The encapsulation of bleomycin within chitosan based polymeric vesicles does not alter its biodistribution2000
Julieann Sludden
Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II1999
Julieann Sludden
Phase I/ Pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion1999
Julieann Sludden
The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations1999
Julieann Sludden
Autoregulation of 5-fluorouracil metabolism1998
Julieann Sludden
Characterisation of dihydropyrimidine dehydrogenase in human colorectal tumours1998
Julieann Sludden
Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects1998
Julieann Sludden
Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer1998
Julieann Sludden
Ethnic differences in catechol O-methyltransferase pharmacogenetics: frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or South-west Asian individuals1998
Julieann Sludden
Liver dihydropyrimidine dehydrogenase activity in human, cynomolgus monkey, rhesus monkey , dog, rat and mouse1998
Julieann Sludden
Polymeric chitosan-based vesicles for drug delivery1998